Geriatric nutrition risk index: a more powerful index identifying muscle mass loss in patients with rheumatoid arthritis
Objective To explore the association of geriatric nutrition risk index (GNRI), a traditional albumin-body weight calculation, with myopenia in patients with rheumatoid arthritis (RA) and compare its ability to identify myopenia with protein indicators. Methods This cross-sectional study was carried out based on a Chinese RA cohort. Clinical data and protein indicators (including albumin, globulin, albumin to globulin ratio, prealbumin, hemoglobin) were collected. GNRI was estimated by serum albumin and body weight. Myopenia was indicated as muscle mass loss measured by bioelectric impedance analysis. Results There were 789 RA patients included with mean age 52.6 ± 12.6 years and 77.6% female. There were 41.3%, 18.0%, 27.5%, 13.2% patients with no (GNRI > 98), low (GNRI 92 to ≤ 98), moderate (GNRI 82 to < 92), and major nutrition-related risk (GNRI < 82). There were 406 (51.5%) RA patients with myopenia, RA patients with major nutrition-related risk had the highest prevalence of myopenia (87.5% vs. 73.3% vs. 50.0% vs. 26.1%). Multivariate logistic analysis showed that compared with no risk, RA patients with low (OR = 3.23, 95% CI: 1.86–5.61), moderate (OR = 9.56, 95% CI: 5.70–16.01), and major nutrition-related risk (OR = 28.91, 95% CI: 13.54–61.71) were associated with higher prevalence of myopenia. Receiver operating characteristic curves showed that GNRI (AUC = 0.79) performed a better identifiable ability toward myopenia than serum albumin (AUC = 0.66) or others indicators (AUC range 0.59 to 0.65), respectively. Conclusion GNRI, an objective and convenient albumin-weight index, may be preferable for identifying myopenia in RA patients. Key Points• We firstly elucidated the association of GNRI with muscle mass loss among RA patients, and compared its ability to identify muscle mass loss with serum albumin or other protein indicators.• Major nutrition-related risk identified by GNRI showed the highest risk of muscle mass loss, GNRI demonstrated a greater ability to identify myopenia in RA patients. which indicated GNRI was an objective and convenient albumin-weight index to identify myopenia in RA patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 43(2024), 4 vom: 04. März, Seite 1299-1310 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pan, Jie [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Geriatric nutrition risk index |
| Anmerkungen: |
© The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10067-024-06918-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055186432 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055186432 | ||
| 003 | DE-627 | ||
| 005 | 20240318064619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-024-06918-3 |2 doi | |
| 035 | |a (DE-627)SPR055186432 | ||
| 035 | |a (SPR)s10067-024-06918-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.83 |2 bkl | ||
| 100 | 1 | |a Pan, Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Geriatric nutrition risk index: a more powerful index identifying muscle mass loss in patients with rheumatoid arthritis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Objective To explore the association of geriatric nutrition risk index (GNRI), a traditional albumin-body weight calculation, with myopenia in patients with rheumatoid arthritis (RA) and compare its ability to identify myopenia with protein indicators. Methods This cross-sectional study was carried out based on a Chinese RA cohort. Clinical data and protein indicators (including albumin, globulin, albumin to globulin ratio, prealbumin, hemoglobin) were collected. GNRI was estimated by serum albumin and body weight. Myopenia was indicated as muscle mass loss measured by bioelectric impedance analysis. Results There were 789 RA patients included with mean age 52.6 ± 12.6 years and 77.6% female. There were 41.3%, 18.0%, 27.5%, 13.2% patients with no (GNRI > 98), low (GNRI 92 to ≤ 98), moderate (GNRI 82 to < 92), and major nutrition-related risk (GNRI < 82). There were 406 (51.5%) RA patients with myopenia, RA patients with major nutrition-related risk had the highest prevalence of myopenia (87.5% vs. 73.3% vs. 50.0% vs. 26.1%). Multivariate logistic analysis showed that compared with no risk, RA patients with low (OR = 3.23, 95% CI: 1.86–5.61), moderate (OR = 9.56, 95% CI: 5.70–16.01), and major nutrition-related risk (OR = 28.91, 95% CI: 13.54–61.71) were associated with higher prevalence of myopenia. Receiver operating characteristic curves showed that GNRI (AUC = 0.79) performed a better identifiable ability toward myopenia than serum albumin (AUC = 0.66) or others indicators (AUC range 0.59 to 0.65), respectively. Conclusion GNRI, an objective and convenient albumin-weight index, may be preferable for identifying myopenia in RA patients. Key Points• We firstly elucidated the association of GNRI with muscle mass loss among RA patients, and compared its ability to identify muscle mass loss with serum albumin or other protein indicators.• Major nutrition-related risk identified by GNRI showed the highest risk of muscle mass loss, GNRI demonstrated a greater ability to identify myopenia in RA patients. which indicated GNRI was an objective and convenient albumin-weight index to identify myopenia in RA patients. | ||
| 650 | 4 | |a Geriatric nutrition risk index |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Muscle mass loss |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Myopenia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rheumatoid arthritis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wu, Tao |4 aut | |
| 700 | 1 | |a Ma, Jian-Da |4 aut | |
| 700 | 1 | |a Jia, Pei-Wen |4 aut | |
| 700 | 1 | |a Zou, Yao-Wei |4 aut | |
| 700 | 1 | |a Ouyang, Zhi-Ming |4 aut | |
| 700 | 1 | |a Zheng, Hu-Wei |4 aut | |
| 700 | 1 | |a Lin, Jian-Zi |4 aut | |
| 700 | 1 | |a Zhang, Qian |4 aut | |
| 700 | 1 | |a Lu, Ye |4 aut | |
| 700 | 1 | |a Chen, Le-Feng |4 aut | |
| 700 | 1 | |a Yang, Ze-Hong |4 aut | |
| 700 | 1 | |a Zhu, Ying-Ying |4 aut | |
| 700 | 1 | |a Song, Qing-Yang |4 aut | |
| 700 | 1 | |a Su, Yun |4 aut | |
| 700 | 1 | |a Su, Lin-Wang |4 aut | |
| 700 | 1 | |a Dai, Wei |4 aut | |
| 700 | 1 | |a Dai, Jun |0 (orcid)0000-0001-7930-2885 |4 aut | |
| 700 | 1 | |a Dai, Lie |0 (orcid)0000-0001-6596-8889 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d Springer International Publishing, 1982 |g 43(2024), 4 vom: 04. März, Seite 1299-1310 |w (DE-627)SPR008480389 |w (DE-600)1480901-1 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:4 |g day:04 |g month:03 |g pages:1299-1310 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10067-024-06918-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 936 | b | k | |a 44.83 |q VZ |
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 4 |b 04 |c 03 |h 1299-1310 | ||